Novartis continues to make progress with its proposed multi-billion-dollar acquisition of eyecare firm Alcon after a number of anti-trust watchdogs gave the transaction the all-clear, albeit with conditions attached. Earlier this month, Novartis received regulatory clearance in the EU and Canada ...
Please Login to read the full article.
